Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > The buyout is this year 2024

<< Previous

Bullboard Posts

Next >>

Comment by CMHarring218431on Jan 31, 2024 2:27pm

151 Views

Post# 35855426

RE:The buyout is this year 2024

The word on the street huh? I really think if there were rumors out there, we would see more accumulation and positive price action. I think you are impatient. Started posting in October and after just reading some of them, I think you thought you were going to make a quick score.

How are you connected to the word on the street? Give us some more juicy tidbits

<< Previous

Bullboard Posts

Next >>

3 Mid-Sized Stocks to Consider This Season